Search results: Sage Journals

Restricted accessOtherFirst published April, 1995

Interim Analyses: An FDA Reviewer's Experience and Perspective *

A. J. Sankoh

Therapeutic Innovation & Regulatory Science

Restricted accessResearch articleFirst published September, 2008

Some Guidelines for Interim Data Review of Clinical Trial Data

Dennis W. King, Jeremy D. Jokinen

Therapeutic Innovation & Regulatory Science

Restricted accessOtherFirst published January, 1999

Interim Analyses: An Update of an FDA Reviewer's Experience and Perspective *

A. J. Sankoh

Therapeutic Innovation & Regulatory Science

Restricted accessResearch articleFirst published July, 1986

Interim Analyses in Randomized Clinical Trials

Stuart J. Pocock, Nancy L. Geller

Therapeutic Innovation & Regulatory Science

Restricted accessResearch articleFirst published February, 2017

The Selection of an Interim CEO

Christine H. Mooney, Matthew Semadeni, Idalene F. Kesner

Journal of Management

Restricted accessResearch articleFirst published April, 1997

Application of Adaptive Interim Analysis in Pharmacology

Ludwig A. Hothorn, Ullrich Martin

Therapeutic Innovation & Regulatory Science

Restricted accessResearch articleFirst published August, 2016

Effects of Interim Assessments Across the Achievement Distribution

Spyros Konstantopoulos, Wei Li, Shazia R. Miller [...]

Educational and Psychological Measurement

Restricted accessOtherFirst published July, 1993

Discussion for Interim Analysis and Sample Size Reestimation

Karl E. Peace

Therapeutic Innovation & Regulatory Science

Restricted accessResearch articleFirst published May, 2003

Ron Brown

Review & Expositor

Restricted accessOtherFirst published July, 2003

An Example of an Unblinded,Third-Party Interim Analysis for Sample Size Re-Estimation

Simon Kirby, Scott McBride, Lohita Puvanarajan

Therapeutic Innovation & Regulatory Science

Search results

Interim Analyses: An FDA Reviewer's Experience and Perspective *

Some Guidelines for Interim Data Review of Clinical Trial Data

Interim Analyses: An Update of an FDA Reviewer's Experience and Perspective *

Interim Analyses in Randomized Clinical Trials

The Selection of an Interim CEO

Application of Adaptive Interim Analysis in Pharmacology

Effects of Interim Assessments Across the Achievement Distribution

Discussion for Interim Analysis and Sample Size Reestimation

Interim or Intentional Interim©

An Example of an Unblinded,Third-Party Interim Analysis for Sample Size Re-Estimation

Search results

Interim Analyses: An FDA Reviewer's Experience and Perspective *

Some Guidelines for Interim Data Review of Clinical Trial Data

Interim Analyses: An Update of an FDA Reviewer's Experience and Perspective *

Interim Analyses in Randomized Clinical Trials

The Selection of an Interim CEO

Application of Adaptive Interim Analysis in Pharmacology

Effects of Interim Assessments Across the Achievement Distribution

Discussion for Interim Analysis and Sample Size Reestimation

Interim or Intentional Interim©

An Example of an Unblinded,Third-Party Interim Analysis for Sample Size Re-Estimation